Johnson & Johnson
Executive Summary
Ortho Biotech extends a March 1990 agreement with Xoma which covers the development of Xoma's CD5+ and other immunoconjugates for graft v. host disease and organ transplant rejection to include Type I diabetes and other uses except rheumatoid arthritis. On June 10, an FDA advisory panel recommended approval of CD5+ in treating GvHD. The drug is in Phase I for the treatment of Type I diabetes and Phase II for inflammatory bowel disease. Under a 1990 pact, Ortho will market the product under the Orthozyme brandname.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth